Baseline levels and decrease in serum soluble intercellular adhesion molecule-1 during chemotherapy predict objective response and survival in patients who have advanced non-small-cell lung cancer.

abstract：BACKGROUND:Malignant pleural effusion (MPE) has a profound impact on quality of life and survival in patients with lung cancer. Identification of the factors within the tumor and its environment that mediate MPE is still lacking. PATIENTS AND METHODS:Intratumoral microvessel density (MVD), endothelial cell and pericyt...

journal_title：Clinical lung cancer

authors： Damianovich M,Hout Siloni G,Barshack I,Simansky DA,Kidron D,Dar E,Avivi C,Onn A

更新日期：2013-11-01 00:00:00

abstract：BACKGROUND:The primary objective of this study was to evaluate the association between radiation sensitivity of the lungs and candidate single nucleotide polymorphisms (SNP) in genes implicated in radiation-induced toxicity. METHODS:Patients with lung cancer who received radiation therapy (RT) had pre-RT and serial po...

journal_title：Clinical lung cancer

authors： Kelsey CR,Jackson IL,Langdon S,Owzar K,Hubbs J,Vujaskovic Z,Das S,Marks LB

更新日期：2013-05-01 00:00:00

abstract：INTRODUCTION:Currently, the role of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors as adjuvant therapy for early-stage non-small-cell lung cancer after complete surgical tumor resection remains under investigation. We present the rationale and study design for the ADAURA (ClinicalTrials.gov identifi...

journal_title：Clinical lung cancer

authors： Wu YL,Herbst RS,Mann H,Rukazenkov Y,Marotti M,Tsuboi M

更新日期：2018-07-01 00:00:00

abstract：:An early phase II study of topotecan produced favorable results in a small number of untreated and previously treated patients with small-cell lung cancer (SCLC). This multicenter study was conducted in patients with relapsed SCLC at 19 medical institutions in Japan. Topotecan 1.0 mg/m2/day was administered for 5 cons...

journal_title：Clinical lung cancer

authors： Takeda K,Negoro S,Sawa T,Nakagawa K,Kawahara M,Isobe T,Kudoh S,Masuda N,Niitani H,Fukuoka M

更新日期：2003-01-01 00:00:00

abstract：:Historically, malignant pleural mesothelioma patients with potentially resectable disease have been treated with surgery and radiation alone. With improvements in systemic and intrapleural treatment options, a movement toward multi-modality therapy has become more common. Systemic treatment options largely consist of ...

journal_title：Clinical lung cancer

authors： Tsao AS,Mehran R,Roth JA

更新日期：2009-01-01 00:00:00

abstract：BACKGROUND:First-line treatment of non-small-cell lung cancer (NSCLC) has undergone a paradigm shift to platinum combination therapy together with an immune checkpoint inhibitor (ICI). Bevacizumab is expected to enhance not only chemotherapy but also the efficacy of ICIs through blockade of vascular endothelial growth ...

journal_title：Clinical lung cancer

authors： Shiraishi Y,Kishimoto J,Tanaka K,Sugawara S,Daga H,Hirano K,Azuma K,Hataji O,Hayashi H,Tachihara M,Mitsudomi T,Seto T,Nakagawa K,Yamamoto N,Okamoto I

更新日期：2020-09-01 00:00:00

abstract：BACKGROUND:Patients with advanced non-small-cell lung cancer (NSCLC) and poor performance status (PS) are often excluded from trials. Gefitinib is a safe oral agent that may benefit these patients. PATIENTS AND METHODS:Seventy-two patients with poor PS and advanced NSCLC were enrolled onto this study of gefitinib 250 ...

journal_title：Clinical lung cancer

authors： Spigel DR,Hainsworth JD,Burkett ER,Burris HA,Yardley DA,Thomas M,Jones SF,Dickson NR,Scullin DC,Bradof JE,Rubinsak JR,Brierre JE,Greco FA

更新日期：2005-09-01 00:00:00

abstract：:The treatment landscape of small-cell lung cancer is rapidly evolving. Results of the first-line randomized trial comparing etoposide/carboplatin/placebo with etoposide/carboplatin/atezolizumab (IMpower-133) were recently published, showing a longer progression-free survival and overall survival for patients receiving...

journal_title：Clinical lung cancer

authors： Pacheco J,Bunn PA

更新日期：2019-05-01 00:00:00

abstract：INTRODUCTION:Small-cell lung cancer (SCLC) is a highly vascularized tumor. ASA404 is a tumor vascular disrupting agent. This is the first trial to report the effects of combining chemotherapy with ASA404 in SCLC. METHODS:Patients with untreated metastatic SCLC were treated with carboplatin (area under curve, 6) plus p...

journal_title：Clinical lung cancer

authors： Früh M,Cathomas R,Siano M,Tscherry G,Zippelius A,Mamot C,Erdmann A,Krasniqi F,Rauch D,Simcock M,Küttel E,Fustier P,Pless M,Swiss Group for Clinical Cancer Research.

更新日期：2013-01-01 00:00:00

abstract：:We present a rare case of recurrent multiple lesions of bronchial epithelial-myoepithelial carcinoma in a 74-year-old man treated with local resection. Two cellular types were found: epithelial cells and myoepithelial cells. The patient remains asymptomatic at 4-years of follow-up, supporting the fact that epithelial-...

journal_title：Clinical lung cancer

authors： Muslimani AA,Kundranda M,Jain S,Daw HA

更新日期：2007-05-01 00:00:00

abstract：BACKGROUND:Serum tumor markers are considered a negative prognostic factor in early-stages NSCLC but its role in advanced disease is controversial. The aim of this study is to analyze the prognostic value of tumor markers in advanced NSCLC. PATIENTS AND METHODS:Two hundred and seventy seven patients diagnosed in our i...

journal_title：Clinical lung cancer

authors： Cedrés S,Nuñez I,Longo M,Martinez P,Checa E,Torrejón D,Felip E

更新日期：2011-05-01 00:00:00

abstract：INTRODUCTION:In the phase III LUX-Lung 8 trial, afatinib significantly improved progression-free survival (PFS) and overall survival (OS) versus erlotinib in patients with squamous cell carcinoma (SCC) of the lung progressing during or after platinum-based chemotherapy. Patient-reported outcomes (PROs) and health-relat...

journal_title：Clinical lung cancer

authors： Felip E,Hirsh V,Popat S,Cobo M,Fülöp A,Dayen C,Trigo JM,Gregg R,Waller CF,Soria JC,Goss GD,Gordon J,Wang B,Palmer M,Ehrnrooth E,Gadgeel SM

更新日期：2018-01-01 00:00:00

abstract：BACKGROUND:Hormesis is a favorable biological response to low toxin exposure. In the case of radiation, large doses are carcinogenic, but low doses might be protective. In the current study, we analyzed lung cancer incidence in high-impact radiation states where nuclear testing occurred and compared it with lung cancer...

journal_title：Clinical lung cancer

authors： Lehrer S,Rosenzweig KE

更新日期：2015-03-01 00:00:00

abstract：BACKGROUND:The real-world effect of anti-programmed death ligand 1 (PD-L1) therapies is unclear. We compared US patients who received second-line therapy for non-small-cell lung cancer (NSCLC) before and shortly after US Food and Drug Administration (FDA) approval of PD-L1 inhibitors. PATIENTS AND METHODS:Patients in ...

journal_title：Clinical lung cancer

authors： Schwartzberg L,Korytowsky B,Penrod JR,Zhang Y,Le TK,Batenchuk C,Krug L

更新日期：2019-07-01 00:00:00

abstract：PURPOSE:Lung cancer is an epidemic disease in developing countries. Incorporation of new active drugs in the neoadjuvant treatment of operable patients might lead to improved outcomes. Postchemotherapy mediastinal-based treatment decisions allow for in vivo testing of activity and could help to determine the ideal loca...

journal_title：Clinical lung cancer

authors： Martins RG,Dienstmann R,de Biasi P,Dantas K,Santos V,Toscano E,Roriz W,Zamboni M,Sousa A,Small IA,Moreira D,Ferreira CG,Zukin M

更新日期：2007-01-01 00:00:00

abstract：:During the past decade, the recognition of an ever-expanding list of driver oncogenic mutations in non-small-cell lung cancer has resulted in rapid therapeutic advances. Since the first description of the echinoderm microtubule-associated protein-like 4 anaplastic lymphoma kinase (EML4-ALK) rearrangement in 4% of case...

journal_title：Clinical lung cancer

authors： Matikas A,Kentepozidis N,Georgoulias V,Kotsakis A

更新日期：2016-11-01 00:00:00

abstract：INTRODUCTION:Maintenance therapy is a new treatment paradigm for advanced non-small-cell lung cancer (NSCLC). We conducted a meta-analysis to evaluate its clinical efficacy in NSCLC and compared the efficacy of chemotherapy, epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), and other treatment ap...

journal_title：Clinical lung cancer

authors： Zhang C,Huang C,Wang J,Wang X,Li K

更新日期：2015-09-01 00:00:00

abstract：BACKGROUND:The aim of this trial was to determine feasibility of incorporating bevacizumab (B) into concurrent chemoradiotherapy (CRT) for locally advanced non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS:Patients with unresectable stage III NSCLC, performance status of 0 to 1, and adequate organ function were...

journal_title：Clinical lung cancer

authors： Wozniak AJ,Moon J,Thomas CR Jr,Kelly K,Mack PC,Gaspar LE,Raben D,Fitzgerald TJ,Pandya KJ,Gandara DR

更新日期：2015-09-01 00:00:00

abstract：:Activating mutations in the epidermal growth factor receptor (EGFR) gene are extremely rare in small-cell lung cancer (SCLC). Here, we present a case of an EGFR-mutant gefitinib-responsive non-small-cell lung cancer (NSCLC) of adenocarcinoma histology occurring in a never-smoker followed by subsequent diagnosis of met...

journal_title：Clinical lung cancer

authors： Alam N,Gustafson KS,Ladanyi M,Zakowski MF,Kapoor A,Truskinovsky AM,Dudek AZ

更新日期：2010-09-01 00:00:00

abstract：PURPOSE:We conducted a phase I trial of the topoisomerase I inhibitor topotecan for the purpose of determining the maximum tolerated dose (MTD) and the dose-limiting toxicities (DLTs) of topotecan when administered weekly to patients with advanced non-small-cell lung cancer. PATIENTS AND METHODS:Twelve patients with s...

journal_title：Clinical lung cancer

authors： Masuda N,Matsui K,Negoro S,Takeda K,Kudoh S,Nakagawa K,Mukaiyama A,Arase H,Yoshida P,Ijima T,Takada M,Fukuoka M

更新日期：2010-07-01 00:00:00

abstract：INTRODUCTION:To prospectively evaluate the frequency and spectrum of incidental findings (IF) in a 5-year lung cancer screening program with low-dose spiral computed tomography (CT) and to estimate the additional costs of their imaging workup incurred from subsequent radiologic follow-up evaluation. MATERIALS AND METH...

journal_title：Clinical lung cancer

authors： Priola AM,Priola SM,Giaj-Levra M,Basso E,Veltri A,Fava C,Cardinale L

更新日期：2013-03-01 00:00:00

abstract：:Multiple studies have confirmed the value of radiation therapy in limited-stage small-cell lung cancer. The appropriate dose of radiation and the optimal fractionation scheme, however, remain controversial. This article will examine the history of radiation therapy in the management of small-cell lung cancer. It will ...

journal_title：Clinical lung cancer

authors： Roof KS,Fidias P,Lynch TJ,Choi NC

更新日期：2003-05-01 00:00:00

abstract：:Metastatic non-small-cell lung cancer is generally not considered to be curable, and the overall 5-year survival rate is less than 1%. Despite this poor prognosis, palliative chemotherapy can increase time and quality of life in the advanced-disease setting. New chemotherapy treatments and targeted therapies are avail...

journal_title：Clinical lung cancer

authors： Bosch-Barrera J,Quer N,Brunet J

更新日期：2011-11-01 00:00:00

abstract：BACKGROUND:Evidence favoring a multidisciplinary team (MDT) approach in the treatment of lung cancer is scarce, especially in the United States. The purpose of the present investigation was to evaluate survival outcomes of lung cancer patients treated with an MDT compared with a traditional care model. PATIENTS AND ME...

journal_title：Clinical lung cancer

authors： Bilfinger TV,Albano D,Perwaiz M,Keresztes R,Nemesure B

更新日期：2018-07-01 00:00:00

abstract：BACKGROUND:The programmed death 1/programmed death-ligand 1 (PD-L1) pathway reportedly is as an important factor determining effects of immunotherapy; however, its prognostic impact is controversial, and its association with the surrounding immune microenvironment has not yet been elucidated. PATIENTS AND METHODS:We r...

journal_title：Clinical lung cancer

authors： Handa Y,Tsutani Y,Shiroma N,Kai Y,Mimae T,Miyata Y,Takeshima Y,Arihiro K,Okada M

更新日期：2020-07-01 00:00:00

abstract：:Vascular endothelial growth factor (VEGF) is regulated by the hypoxia-inducible factor 1 (HIF1) pathway and is implicated in tumor progression and patient survival in many types of cancer. Insulin-like growth factor-binding protein 3 (IGFBP3) is also regulated by HIF1 but works in a completely different manner by modu...

journal_title：Clinical lung cancer

authors： Gharib TG,Chen G,Huang CC,Misek DE,Iannettoni MD,Hanash SM,Orringer MB,Beer DG

更新日期：2004-03-01 00:00:00

abstract：BACKGROUND:In lung adenocarcinoma, inactivation of the tumor suppressor p53 may abrogate a safeguard mechanism preventing the development of tumors with activating mutations in EGFR or KRAS. To assess this hypothesis, we analyzed TP53 mutations and downregulation of p14(arf), a negative regulator of p53 activated by on...

journal_title：Clinical lung cancer

authors： Cortot AB,Younes M,Martel-Planche G,Guibert B,Isaac S,Souquet PJ,Commo F,Girard P,Fouret P,Brambilla E,Hainaut P,Soria JC

更新日期：2014-03-01 00:00:00

abstract：:Radiation Therapy Oncology Group (RTOG) 3505 is a randomized phase 3 study of concurrent chemoradiation followed by immune checkpoint inhibitor therapy or placebo in patients with locally advanced non-small-cell lung cancer (NSCLC). Patients with surgically unresectable stage 3 NSCLC will receive thoracic radiotherapy...

journal_title：Clinical lung cancer

authors： Gerber DE,Urbanic JJ,Langer C,Hu C,Chang IF,Lu B,Movsas B,Jeraj R,Curran WJ,Bradley JD

更新日期：2017-05-01 00:00:00

abstract：INTRODUCTION:Lung cancer is the leading cause of cancer-related death. Many patients with lung cancer are in its advanced stages at the time of diagnosis. The 5-year survival rate for lung cancer is 10% to 20%, and the prognosis for patients with lung cancer is still poor. The crosslinked N-terminal telopeptide of type...

journal_title：Clinical lung cancer

authors： Tamiya M,Kobayashi M,Morimura O,Yasue T,Nakasuji T,Satomu M,Kohei O,Takayuki S,Morishita N,Suzuki H,Sasada S,Okamoto N,Hirashima T,Kawase I

更新日期：2013-01-01 00:00:00

abstract：BACKGROUND:Major guidelines do not recommend routine molecular profiling of lung squamous-cell carcinoma (LUSC) because the prevalence of actionable alterations is thought to be low. Increased utilization of next-generation sequencing (NGS), particularly with cell-free circulating tumor DNA, facilitates reevaluation of...

journal_title：Clinical lung cancer

authors： Lam VK,Tran HT,Banks KC,Lanman RB,Rinsurongkawong W,Peled N,Lewis J,Lee JJ,Roth J,Roarty EB,Swisher S,Talasaz A,Futreal PA,Papadimitrakopoulou V,Heymach JV,Zhang J

更新日期：2019-01-01 00:00:00